869631-11-8

869631-11-8 structure
869631-11-8 structure
  • Name: O-Desethyl candesartan cilexetil
  • Chemical Name: 1-cyclohexyloxycarbonyloxyethyl 2-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-benzimidazole-4-carboxylate
  • CAS Number: 869631-11-8
  • Molecular Formula: C31H30N6O6
  • Molecular Weight: 582.60600
  • Create Date: 2018-06-17 12:08:52
  • Modify Date: 2026-06-30 18:03:37

Name 1-cyclohexyloxycarbonyloxyethyl 2-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-benzimidazole-4-carboxylate
Synonyms Candestan Cilexetil Impurity 2 Impurity B)
Candestan Impurity II
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate
Candestan Cilexetil Impurity Ⅱ
2,3-Dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-4-carboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester
Candestan Impurity B
Candestan Cilexetil ImpuritⅠ: O-Desethyl Candestan Cilexetil( 2,3-Dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole-4-cboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester)
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-cboxylate
Candestan Cilexetil Impurity B (Candestan Cilexetil O-Desethyl Analog)
2,3-Dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-1H-benziMidazole-4-cboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester
Candestan Imp B
Candestan Cilexetil IMpurity B
1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl 2,3-dihydro-2-oxo-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-benzimidazole-4-cboxylate
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-cboxylate (Candestan cilexetil Impurity)
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl) -2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-cboxylate
Candestan Cilexetil Impurity 2(Candestan Cilexetil Impurity B)
desethyl-condesartan
2-oxocandesartan cilexetil
Candestan Cilexetil O-Desethyl Analog
Candestan Cilexetil ImpuritⅠ: O-Desethyl Candestan Cilexetil( 2,3-Dihydro-2-oxo-3-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1H-benzimidazole-4-cboxylic Acid 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl Ester)
Candestan Cilexetil Imp. B : (1RS)-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-oxo- 3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-2,3-dihydro-1H- benzimidazole-4-cboxylate
O-Desethyl Candesartan Cilexetil
Candestan Cilexetil impurity BQ: What is Candestan Cilexetil impurity B Q: What is the CAS Number of Candestan Cilexetil impurity B Q: What is the storage condition of Candestan Cilexetil impurity B Q: What e the applications of Candestan Cilexetil impurity B
O-Desethyl Candestan Cilexetil
Candestan Cilexetil Impurity B (Desethyl Candestan Cilexetil)
1-(Cyclohexyloxycbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl) methyl)-2-hydroxy-1H-benzo[d]imidazole-7-cboxylate
Candestan cilexetil impurity II
(1RS)-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-oxo-3-[[2'-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-2,3-dihydro-1H-benzimidazole-4- cboxylate
Candestan Impurity 1
CNS-desethyl
1H-Benzimidazole-4-cboxylic acid, 2,3-dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
Candestan Cilexetil Related Compound B (1-(Cyclohexyloxycbonyloxy)ethyl 1-{[2''-(1H- tetrazol-5
Candesartan Cilexetil Impurity 2
(1RS)-1-[[(Cyclohexyloxy)carbonyl]-oxy]ethyl 2-Oxo-3-[[2'-(1H-tetrazol-5-yl-)-biphenyl-4-yl]methyl]
1-cyclohexyloxycbonyloxyethyl 2-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1H-benzimidazole-4-cboxylate
candestan cilexetil impurity1358
desethyl-CNS
UNII-JC6R5VA63B
Candestan Cilexetil Related Compound B
Molecular Formula C31H30N6O6
Molecular Weight 582.60600
Exact Mass 582.22300
PSA 154.34000
LogP 5.62600
RIDADR NONH for all modes of transport

~%

869631-11-8 structure

869631-11-8

Literature: KRKA, D.D. NOVO MESTO Patent: WO2007/42161 A1, 2007 ; Location in patent: Page/Page column 16-17 ;

~88%

869631-11-8 structure

869631-11-8

Literature: Havllcek, Jaroslav; Mandelova, Zuzana; Weisemann, Ruediger; Strelec, Ivo; Placek, Lukas; Radl, Stanislav Collection of Czechoslovak Chemical Communications, 2009 , vol. 74, # 2 p. 347 - 362

~70%

869631-11-8 structure

869631-11-8

Literature: Havllcek, Jaroslav; Mandelova, Zuzana; Weisemann, Ruediger; Strelec, Ivo; Placek, Lukas; Radl, Stanislav Collection of Czechoslovak Chemical Communications, 2009 , vol. 74, # 2 p. 347 - 362

~%

869631-11-8 structure

869631-11-8

Literature: TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC. Patent: WO2006/122254 A2, 2006 ; Location in patent: Page/Page column 12; 13 ;

~%

869631-11-8 structure

869631-11-8

Literature: TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC. Patent: WO2006/122254 A2, 2006 ; Location in patent: Page/Page column 12; 13 ;
Precursor  2

DownStream  0

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.